

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

10 - 16 November 2025



Port potassium chloride inventory in the first week of November 2025

Port potassium chloride inventory in the first week of November 2025 was approximately 2.097 million tons, an increase of 58,000 tons compared to the end of October, and a decrease of 1.183 million tons compared to the same period last year. The potassium chloride (import) index was 107.94, down 38.18% from the highest point of 174.60 (June 21, 2022), and up 85.30% from the lowest point of 58.25 in August 2020. **(China Inorganic Salts Industry Association)**

India Initiates Anti-Dumping Investigation on Butyl Rubber from China

On October 31, 2025, the Indian Ministry of Commerce and Industry announced that, in response to an application submitted by Reliance Sibur Elastomers Private Limited, an Indian company, it had initiated an anti-dumping investigation on butyl rubber (Halo-Isobutene-Isoprene Rubber, HIIR) originating in or imported from China, Singapore, and the United States. **(Official Gazette of India)**

Argentina Issues Final Anti-Dumping Ruling on PVC (Polyvinyl chloride) Profiles from China

On October 30, 2025, the Argentine Ministry of Economy issued Announcement No. 1680 of 2025, issuing a negative final ruling on the sunset review and changed circumstances review of the anti-dumping duties on PVC profiles originating from China used in the manufacture of doors, windows, and partitions, deciding not to continue the anti-dumping measures. **(Official Argentine Gazette)**

China's domestic biotech industry is becoming a global force

China's biotech sector is gaining global influence, marked by innovative drugs like Dical Pharma's sunvozertinib, the first China-originated therapy for a specific lung cancer approved by the U.S. FDA (Food and Drug Administration) and included in NCCN (National Comprehensive Cancer Network) guidelines. This breakthrough reflects a strategic shift from generic production to original drug development. **(China Daily)**

China approves rice-derived recombinant human albumin injection

China has approved the world's first rice-derived recombinant human albumin injection, a groundbreaking treatment for hypoalbuminemia in liver cirrhosis patients. Developed by Wuhan Healthgen Biotechnology, it uses genetically modified rice as a bioreactor to produce this vital blood protein, offering a safe and scalable alternative to plasma-derived sources. **(National Medical Products Administration)**